Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 August 2018 Photo Xolisa Mnukwa
Haemophilia workshop the first of its kind at UFS
The UFS Department of Haematology and Cell Biology is producing quality medical graduates, addressing the high demand for trained graduates. Dr Anneke van Marle, Haematologist in the department, presented a lecture to final-year medical students on muscle and soft-tissue bleeding in haemophilia.

The Medical and Scientific Advisory Council (MASAC) of the South African Haemophilia Foundation (SAHF) has identified a need for more in-depth training of junior doctors on the basic aspects of the bleeding disorder haemophilia. 

Addressing this need in the sector, the Department of Haematology and Cell Biology at the University of the Free State (UFS) recently hosted a training workshop specifically targeting final-year medical students before they enter practice.

The Novo Nordisk Haemophilia Foundation is sponsoring this countrywide haemophilia training.

According to Jaco Joubert, Senior Lecturer and Pathologist in the Department of Haematology and Cell Biology, the department is very active in the field of haemophilia treatment, research and training, with representation on the Executive Committee of the Medical and Scientific Advisory Council of the South African Haemophilia Foundation.

Function with confidence

“The UFS Department of Haematology and Cell Biology has taken a proactive approach, by being the first department in South Africa to offer this training course to final-year medical students at the UFS; an investment in the future. The department runs the Bloemfontein Haemophilia Treatment Centre – which is the main haemophilia treatment and referral centre for patients from the Free State and Northern Cape. It is therefore ideally positioned to offer such training to students,” said Joubert.

Proactive role

The training workshop empowered and equipped students with more extensive knowledge on the practical aspects of managing patients with haemophilia; the various treatment products currently available in South Africa and laboratory diagnostic approaches in complicated cases. “This will enable students to function with more confidence during their internship and community service years,” said Joubert. 

He believes a training workshop of this calibre showcases the proactive role the department and the university is taking in the advancement of haemophilia training in South Africa.

News Archive

Science is diversifying the uses of traditional medicines
2017-07-17

Description: Dr Motlalepula Matsabisa  Tags: traditional medicines, Indigenous Knowledge Systems, Dr Motlalepula Matsabisa, Malaria, priority disease  

Dr Motlalepula Matsabisa.
Photo: Anja Aucamp

According to the World Health Organisation, a large majority of the African population are making use of traditional medicines for health, socio-cultural, and economic purposes. In Africa, up to 80% of the population uses traditional medicines for primary healthcare.

The Indigenous Knowledge Systems (IKS) was identified as a lead programme under the directorship of Dr Motlalepula Matsabisa. Research undertaken by the IKS Lead Programme focuses on some key priority diseases of the country and region – including malaria, HIV, cancer, and diabetes.
 
Not just a plant or tree

Malaria is a priority disease and is prevalent in rural and poor areas, resulting in many traditional health practitioners claiming to treat and cure the disease. There may well be substance to these claims, since as much as 30% of the most effective current prescription medicines are derived from plants.  For instance, chloroquine, artemisinin for malaria, Metformin for diabetes, Vincristine and Vinblastine for cancer, are plant-derived drugs.  

Dr Matsabisa’s current research is investigating a South African medicinal plant that has been shown to have in vitro antiplasmodial activity, with subsequent isolation and characterisation of novel non-symmetrical sesquiterpene lactone compounds offering antimalarial activity. These novel compounds are now patented in South Africa and worldwide. This research is part of the UFS and South Africa’s strive to contribute to the regional and continental malaria problem. The UFS are thus far the only university that has been granted a permit by the Medicines Control Council to undertake research on cannabis and its potential health benefits.

“All of these projects are aimed
at adding value through the scientific
research of medicinal plants, which
can be used for treating illnesses,
diseases, and ailments.”

Recognition well deservedThrough Dr Matsabisa’s research input and contributions to the development of the pharmacology of traditional medicines, he recently became the first recipient of the International Prof Tuhinadrin Sen Award from the International Society of Ethnopharmacology (ISE) and the Society of Ethnopharmacology in India. ISE recognises outstanding contributions by researchers, scientists, and technologists in the area of medicinal plant research and ethnopharmacology internationally.

More recently, Dr Matsabisa undertook research projects funded by the National Research Foundation, as well as the Department of Science and Technology, on cancer, gangrene, and diabetes. He is also involved in a community project to develop indigenous teas with the community. He says, “All of these projects are aimed at adding value through the scientific research of medicinal plants, which can be used for treating illnesses, diseases, and ailments”.

Dr Matsabisa has worked with many local and international scientists on a number of research endeavours. He is grateful to his colleagues from the Department of Pharmacology in the Faculty of Health Sciences, who are dedicated to science research and the research of traditional medicines. The IKS unit also received immense support from the Directorate of Research Development.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept